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Medoxomil and Chlorthalidone to Be Utilized in Their Determination
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ABSTR ACT: The recently approved angiotensin II receptor blocker, azilsartan medoxomil (AZL), was determined spectrophotometrically and spectrofluorimetrically in its combination with chlorthalidone (CLT) in their combined dosage form. The UV-spectrophotometric technique depends on simultaneous measurement of the first derivative spectra for AZL and CLT at 286 and 257 nm, respectively, in methanol. The spectrofluorimetric technique depends
on measurement of the fourth derivative of the synchronous spectra intensities of AZL in presence of CLT at 298 nm in methanol. The effects of different
solvents on spectrophotometric and spectrofluorimetric responses were studied. For, the spectrofluorimetric study, the effect of pH and micelle-assisted
fluorescence enhancement were also studied. Linearity, accuracy, and precision were found to be satisfactory over the concentration ranges of 8–50 µg mL -1
and 2–20 µg mL -1 for AZL and CLT, respectively, in the spectrophotometric method as well as 0.01–0.08 µg mL -1 for AZL in the spectrofluorimetric
method. The methods were successfully applied for the determination of the studied drugs in their co-formulated tablets. The developed methods are inexpensive and simple for the quality control and routine analysis of the cited drugs in bulk and in pharmaceuticals.
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1. Introduction

Azilsartan medoxomil (AZL) (5-methyl-2-oxo-1,3-dioxol-4yl)
methyl 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol3-yl) biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate—Figure 1a—is practically insoluble in water, freely soluble
in methanol and dimethylsulfoxide, soluble in acetic acid,
slightly soluble in acetone and acetonitrile, and sparingly soluble in tetrahydrofuran and 1-octanol.1 Azilsartan, the active
metabolite of AZL, is a novel non-peptide angiotensin II type
1 (AT1) receptor blocker (ARB) that was recently approved for
treatment of hypertension.2 It has a superior ability to control systolic blood pressure (BP) relative to other widely used
ARBs. Greater antihypertensive effects of AZL might be in

part because of its unusually potent and persistent ability to
inhibit binding of angiotensin II to AT1 receptors.3 Preclinical
studies have indicated that AZL may also beneficially affect
cellular mechanisms of cardio-metabolic disease and insulin
sensitizing activity.4 There is only one reported method1 for
determination of AZL alone, and it was applied to its analysis in
plasma. Chlorthalidone (CLT) (2-chloro-5-(1-hydroxy-3-oxoisoindolin-1-yl) benzenesulfonamide)—Figure 1b—is an orally
taken thiazide-like diuretic for controlling hypertension and
edema, including that associated with heart failure.5 CLT has
been determined in different matrices either alone or in combination with other medications using LC,6,7 LC-MS/MS,8
HPTLC,9,10 chemiluminometry,11 spectrophotometry,12 and
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Figure 1. Chemical structures for (a) AZL and (b) CLT.

CE13 techniques. Binary combination therapies of AZL and
CLT proved to induce significant reductions in systolic and
diastolic BP in patients with mild to severe hypertension.14
Accordingly, it is desirable to develop validated simple analytical methods for assay of AZL in its combination with
CLT either in their laboratory prepared mixtures or in their
combined pharmaceutical preparations. Regarding simultaneous determination of CLT and AZL, there is only one LC
reported method15 that was done on a symmetry C18 column
with a mobile phase consisting of methanol:water:acetonitr
ile:0.1% ortho phosphoric acid (30:35:15:5, v/v/v/v) at detection l of 251 nm. To the best of our knowledge, there is no
reported spectrophotometric or spectrofluorimetric methods
for determination of AZL either alone or in its combination
with CLT. Hence, the aim of these studies was to develop and
validate simple, rapid, and inexpensive analytical methods
using the spectrophotometric and spectrofluorimetric techniques for determination of AZL in its combination with CLT
to be applied to their determination in pharmaceuticals. These
newly developed and validated methods can be used for routine analysis and quality control of the cited medications either
separately or in combination without pre-separation.

2. Experimental

2.1. Materials and reagents. All chemicals used were of
analytical reagent grade, and solvents were of HPLC grade.
CLT (certified to contain 98%) was supplied by Ark Pharm.
Inc., IL 60048 USA. AZL (certified to contain 98%) was
supplied by D-L Chiral Chemicals, LLC, NJ 08540, USA.
Edarbyclor® 40/25 mg tablets, batch NDC 64764-0994-30
(Takeda Pharmaceutical Company Limited, Tokyo, Japan),
each labeled to contain 42.68 mg of azilsartan kamedoxomil
(equivalent to 40 mg AZL) and 25 mg CLT were purchased
from commercial sources in the local market. Methanol,
sodium dodecyl sulphate (SDS), cetyltrimethylammonium
bromide (CTAB), and hydroxymethylcellulose (HMC) were
obtained from Sigma-Aldrich, MO, USA, and b-cyclodextrin (b-CD) from TCI, Tokyo Kasei, Japan. O-phosphoric
acid 85% and hydrochloric acid (Fisher Scientific, NJ, USA)
were used. Sodium hydroxide and sodium dihydrogen phosphate were purchased from J.T. Baker, NJ, USA. Phosphate
buffer s olutions (PBSs) (0.02 M) were freshly prepared. SDS,
34
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CTAB, b-CD, and HMC were prepared as 1% w/v aqueous
solutions. Also, 0.1 N NaOH and 0.1 N HCl were prepared.
2.2. Instrument. A lambda 20 UV/Vis spectrometer
(Perkin Elmer, MA, USA) was used for the spectrophotometric measurements, whereas a LS 55 fluorescence spectrometer,
120 V (Perkin Elmer, MA, USA), was used for the spectrofluorimetric measurements. Spectrophotometric measurements and data handling were performed using UV WinLab
1.22 software, whereas fluorescence spectra measurements and
data handling were performed using FL WinLab™ software.
Quartz cells (1 cm) were used. A VWR symphony (SB20) pH
meter (Thermo Orion, Beverly, MA, USA) was used for pH
measurements. Deionized water was prepared using a Barnstead NANO pure diamond analytical ultrapure water system
(Thermo Fischer Scientific, Waltham, MA, USA).
2.3. Standard stock solutions preparation. A total of
10 mg of AZL and CLT were accurately weighed and transferred separately into 10 mL of volumetric flasks. Then, they
were dissolved and made up to volume with methanol to
give concentrations of 1000 µg mL -1 for each. Further dilutions were made separately using the same solvent to prepare
1 µg mL -1 solutions for each.
2.4. Procedures.
2.4.1. Linearity and construction of calibration graphs for
the spectrophotometric technique. Aliquots of AZL and CLT
standard stock solutions (1000 µg mL-1) were separately
transferred into two series of 10 mL Fisherbrand disposable tubes to give final concentrations of 8–50 µg mL-1 and
2–20 µg mL-1 for AZL and CLT, respectively, then completed to 5 mL with methanol, and the contents were mixed
well. The absorbance spectra were recorded against a methanol blank and then the first derivative spectra were obtained
(number of points = 18). The amplitudes at 286 and 257 nm
for AZL and CLT, respectively, were measured and then
plotted versus the corresponding final drug concentration of
AZL and CLT (µg mL-1) to obtain the calibration graphs
and regression equations.
2.4.2. Linearity and construction of calibration graphs for the
spectrofluorimetric technique. Aliquots of AZL standard stock
solution (1 µg mL-1) were transferred into a series of 10 mL
Fisherbrand disposable tubes to give final concentrations in the
range of 0.01–0.08 µg mL-1. Then, completed to 5 mL with
methanol and the contents were mixed well. Relative fluorescence intensity (RFI) of the synchronous spectrofluorimetric
spectra was recorded against a solvent blank using Dl = 110 nm
(slit width for excitation and emission = 10 nm), and then the
fourth derivatives were obtained (number of points = 90). The
amplitudes of the fourth derivative of the synchronous spectra
at 298 nm were measured and plotted versus the corresponding final drug concentration of AZL (µg mL-1) to obtain the
calibration graphs and regression equations.
2.4.3. Preparation of AZL and CLT laboratory prepared
mixtures. For the spectrophotometric method, aliquots of
AZL and CLT standard stock solutions (1,000 µg mL -1)

3. Results and Discussion

The goal of the present investigations was to do some spectrophotometric and spectrophotometric studies on AZL and
CLT in order to develop validated, rapid, sensitive, simple,
inexpensive, and selective spectrophotometric and spectrofluorimetric analytical methods for quantification of AZL in
its combination with CLT. These studies focused on factors
that enhance the absorbance or the intensities for the emission
bands of each analyte.
3.1. Optimization of the experimental conditions for
the spectrophotometric technique. For the spectrophotometric technique, the effect of different diluting solvents such
as methanol, 0.1 N HCl, and 0.1 N NaOH on absorbance
was studied. 0.1 N NaOH showed a slightly higher response
for both drugs (Fig. 2). This solvent can be used for ordinary
UV measurements of AZL or CLT separately at 260 and
232 nm, respectively. Methanol was used as a convenient diluting solvent with satisfactory linearities in the range of 8–50
and 2–20 µg mL -1 for AZL and CLT at 266 and 242 nm,

0.8
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0.7

CLT

0.6
0.5
0.4
0.3
0.2
0.1
0
Methanol

0.1 N HCI

0.1 N NaOH

Figure 2. Effect of different diluting solvents on the zero-order
UV-absorbance spectra of (a) 20 µg mL-1 of AZL at 260 nm and
(b) 8 µg mL-1 of CLT at 232 nm.

r espectively (Fig. 3). The spectra of AZL and CLT in all of the
studied solvents showed severe overlap (Fig. 3). Obtaining the
first derivative for the absorbance spectra of the analyzed drugs
was able to resolve such overlapping between AZL and CLT,
only in methanol, to be utilized for their simultaneous quantitative determination at 286 and 257 nm, respectively (Fig. 4).
3.2. Optimization of the experimental conditions for
the spectrofluorimetric technique.
3.2.1. Effect of diluting solvent. AZL is freely soluble in
methanol, so it was added to the solvent media in at least 10%
of the final volume and then either methanol, 0.1 N HCl,
0.1 N NaOH, or PBS was added to complete the volume. The
influence of these different diluting solvents on the RFI of
AZL and CLT was studied, and methanol was chosen as it
showed the highest RFI (Fig. 5).
3.2.2. Effect of pH. The effect of pH on RFI of AZL and
CLT was investigated and pH 7.5 was found to give slightly
higher RFI for AZL as its pKa value is 6.1, and it will have
higher ionization percentage at this pH (Fig. 6). For CLT
(pKa = 9.4), it is ionized at all of the studied pHs, so the effect
of the studied pH values was not significant (Fig. 6).

3

b
(242 nm)

2.5

Absorbance

were accurately transferred into a series of 10 mL Fisherbrand
disposable tubes to give final concentrations of 9.6, 16.0, and
24.0 µg mL -1 for AZL and 6.0, 10.0, and 15.0 µg mL -1 for
CLT. The procedure described under section “2.4.1” was then
applied. For the spectrofluorimetric method, aliquots of AZL
and CLT standard stock solutions (1 µg mL -1) were accurately transferred into a series of 10 mL Fisherbrand disposable tubes to give final concentrations of 0.0384, 0.0576, and
0.0768 µg mL -1 for AZL and 0.0240, 0.0360, 0.0480 µg mL -1
for CLT. The procedure described under section “2.4.2” was
then applied. For both methods, the recovery percentage was
calculated using the corresponding regression equation.
2.4.4. Sample preparation. 10 tablets of Edarbcyclor® were
weighed and finely powdered after removal of the coat using
a tissue moistened with methanol. A portion of the powder
equivalent to AZL (40 mg) and CLT (25 mg) was introduced
into a 25 mL volumetric flask to which 20 mL methanol were
added and sonicated for 30 min. The solution was made up to
volume using the same solvent and filtered through a Whatman
filter paper, and then filtered again using a 0.2 µm Whatman
inorganic membrane filter. For spectrophotometric analyses,
different aliquots from the prepared sample solutions were
scanned and manipulated using the same procedure described
under section “2.4.1.” For the spectrofluorimetric analyses,
further dilutions were prepared and different aliquots from
the prepared sample solutions were scanned and manipulated
using the same procedure described under section “2.4.2.” The
percentage of recoveries were calculated by referring to the corresponding regression equations.
2.5. Validation. The suggested analytical method was
validated according to ICH guidelines16 with respect to certain parameters such as linearity, limit of detection (LOD)
and limit of quantitation (LOQ ), accuracy, precision, specificity, and stability.

Absorbance
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Figure 3. Zero-order UV-absorbance spectra of (a) 8, 12, 20, 30, and
50 µg mL-1 AZL and (b) 2, 4, 8, 12, 20 µg mL-1 CLT against (c) methanol blank.
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Figure 5. Effect of different diluting solvents on the relative conventional
fluorescence intensities for 0.02 µg mL-1 of AZL and CLT at 381 nm upon
excitation at 260 nm using the described parameters.
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Figure 6. Effect of pH of PBS on the relative conventional fluorescence
intensities for 0.02 µg mL-1 of AZL and CLT at 381 nm upon excitation at
260 nm using the described parameters.

3.2.3. Effect of different organized media. The fluorescence
properties of AZL and CLT in various micellar media were
studied using anionic surfactant (SDS), cationic 
surfactant
(CTAB), as well as different macromolecules such as (b-CD)
and (HMC). Micelles or reversed micelles are able to stabilize
the exited singlet state and delay the decay process, and thus
may enhance the intensity of the emission bands.17 PBS of pH
Analytical Chemistry Insights 2014:9

CTAB
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Water

Figure 7. Effect of different surfactants (1 mL of 1% w/v solution for each)
on the relative conventional fluorescence intensities for 0.02 µg mL-1 of
AZL and CLT at 381 nm upon excitation at 260 nm using the described
parameters.

Figure 4. First derivative for the spectra of (a) 8, 12, 20, 30, and
50 µg mL-1 of AZL and (b) 2, 4, 8, 12, 20 µg mL-1 of CLT against
(c) methanol blank.
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7.5 was used through this study to allow proper ionization of
both analytes. None of the examined surfactants showed significant enhancement in RFI of AZL and CLT (Fig. 7).
3.2.4. Techniques and parameters settings. Satisfactory linearity was obtained for AZL and CLT in methanol at 381 and
330 nm, upon excitation at 260 nm, respectively, at slit width
of excitation and emission of 10 nm (Fig. 8, Table 1). However, the spectra of AZL and CLT in all of the studied solvents showed severe overlap, so they cannot be used for their
simultaneous determination (Fig. 8). Also, synchronous fluorescence was not able to resolve such overlap at l = 10–300 nm
(slit width for excitation and emission = 5–10 nm) (Fig. 9).
Obtaining the fourth derivative for the synchronous fluorescence spectra (l = 110 nm, slit width for excitation and
emission = 10 nm) of the analyzed drugs was able to resolve
such overlap between AZL and CLT, only in methanol, to be
utilized for quantitative determination of AZL in presence of
CLT at 298 nm in their medicinally recommended ratio of
1.6:1, respectively (Fig. 10).
3.3. Validation of the methods.
3.3.1. Linearity and range. Linear relationship between
the responses of AZL or CLT and their corresponding concentrations was obtained. The regression equation y = bC ± a
for each drug was also computed. In these studies, at least five
concentrations for AZL or CLT were used. The linearity of the
calibration curves was validated by the high value of correlation coefficients (r) of the regression equation, small values of
the standard deviation of residuals (Sy/x), and small value of the
percentage relative error (Table 1). The analytical data of the
calibration curves including standard deviations for the slope
and intercept (Sb, Sa) are summarized in Table 1. These data
indicate the linearity of the calibration graphs.
3.3.2. Limit of detection and limit of quantification. LOQ
and LOD were calculated according to ICH recommendations.17 LOD was considered as the minimum concentration
with a signal to noise ratio of at least 3 (S/N ~3), whereas LOQ
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Figure 8. Conventional emission spectra for 0.06 µg mL-1 of (a) AZL and (b) CLT upon excitation at 260 nm against (c) methanol blank using the described
parameters.

was taken as a minimum concentration with a signal to noise
ratio of at least 10 (S/N ~10). Results are given in Table 1.
3.3.3. Accuracy and precision. The satisfactory recovery
percentage results for the assay of AZL and/with CLT in
their laboratory prepared mixtures indicate the accuracy of
the method (Table 2). Repeatability (intra-day) and intermediate precision (inter-day) were assessed using three
concentrations and three replicates of each concentration.
The relative standard deviations were found to be very small
indicating reasonable repeatability and intermediate precision of the proposed method (Table 3).

3.3.4. Specificity. The specificity of the method was investigated by observing any interference encountered from common tablet excipients, and it was confirmed that the signals
measured was caused only by the analytes. The inactive ingredients in Edarbyclor® are mannitol, microcrystalline cellulose, fumaric acid, sodium hydroxide, hydroxypropyl cellulose,
crospovidone, magnesium stearate, hypromellose 2910, talc,
titanium dioxide, ferric oxide red, polyethylene glycol 8000, and
printing ink gray F1. It was found that the excipients did not
interfere with the results (Table 2). For the spectrophotometric
method, it was found that AZL and CLT can be determined

Table 1. Performance data and results of the proposed spectroscopic methods.
ITEM

SPECTROPHOTOMETRIC TECHNIQUE

SPECTROFLUORIMETRIC TECHNIQUE

AZL
(D1)

CLT
(D1)

AZL
(D4)

AZL
(381 nm)

CLT
(330 nm)

Limit of detection, LOD (µg mL-1)

0.977

0.296

0.001

0.001

0.002

Limit of quantitation, LOQ (µg mL-1)

2.960

0.897

0.003

0.004

0.005

Intercept (a)

0.0064

-0.0154

0.7876

41.996

3.5339

Slope (b)

0.0075

0.0224

789.1

6289.8

3922.4

Correlation coefficient (r)

0.9998

0.9999

0.9998

0.9991

0.9996

S.D of residuals (Sy/x)

0.003

0.003

0.478

4.396

2.576

S.D of intercept (Sa)

0.002

0.002

0.267

2.469

2.043

S.D of slope (Sb)

0.001

0.001

8.048

74.453

61.598

Percentage relative error

0.75

0.55

0.76

0.94

1.23

Linearity range (µg/mL)

8.00-50.00

2.00-20.00

0.01-0.08

0.01-0.08

0.01-0.06

Mean recovery ± %R.S.D

99.55 ± 1.69

100.62 ± 1.24

99.94 ± 0.80

99.54 ± 2.09

100.61 ± 2.75
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Figure 9. Synchronous fluorescence spectra for 0.06 µg mL-1 of (a) AZL and (b) CLT upon excitation at 260 nm against (c) methanol blank using the
described parameters.

simultaneously either in their laboratory prepared mixtures or
in their co-formulated tablets (Table 2). On the other hand, the
spectrofluorimetric method was only able to determine AZL
in presence of CLT in methanol (Table 2).
3.3.5. Stability. Stabilities of the standard stock solutions
of AZL and CLT, stored at 2–8°C, were evaluated at various time points for more than one month. The concentrations
of freshly prepared solutions and those aged for one month
were calculated by the methods developed, and the d
 ifference

between them was found to be less than 2%. Also, the prepared solutions for analysis were found to be stable for at
least three days at 2–8°C and for a day at room temperature.
These solutions can therefore be used during this interval of
time without the results being affected.

4. Conclusion

Rapid, sensitive, inexpensive, and simple spectrophotometric and spectrofluorimetric methods were developed and

4th derivative of synchronous fluorescence intensity
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Figure 10. Fourth derivative of the synchronous fluorescence spectra for (a) 0.01, 0.02, 0.04, 0.06, 0.08 µg mL-1 of AZL and (b) 0.01, 0.02, 0.03, 0.04,
0.06 µg mL-1 of CLT against (c) methanol blank using the described parameters.
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Table 2. Assay results for the determination of the studied drugs in their laboratory prepared mixtures and dosage form.
TECHNIQUE

COMPOUND

CLT

Spectrophotometric

SYNTHETIC MIXTURES (CLT:AZL) (1.0:1.6)

DOSAGE FORM (EDARBCYCLOR® TABLETS)

AMOUNT TAKEN
(mg mL -1)

AMOUNT FOUND
(mg mL -1)

% FOUND

AMOUNT TAKEN
(mg mL -1)

AMOUNT FOUND
(mg mL -1)

% FOUND

6.000

6.045

100.74

6.000

6.045

100.74

10.000

9.839

98.39

10.000

10.286

102.86

18.000

17.875

99.31

18.000

17.652

98.07

Mean recovery%

99.48

100.56

± %R.S.D

1.19

2.39

AZL

9.600

9.813

102.22

9.600

9.813

102.22

16.000

15.813

98.83

16.000

16.480

103.00

28.800

28.480

98.89

28.800

28.480

98.89

Mean recovery%

99.98

101.37

± %R.S.D

1.94

2.15

AZL
Spectrofluorimetric

0.0384

0.039

101.26

0.0384

0.037

97.40

0.0576

0.058

100.12

0.0576

0.057

99.30

0.0768

0.077

100.47

0.0768

0.076

98.80

Mean recovery%

100.62

98.50

± %R.S.D

0.58

1.00

Each result is the average of three separate determinations.

Table 3. Intra- and inter-day validation for the spectroscopic methods.
TECHNIQUE

MEDICATION

AZL
Spectrophotometric
CLT

Spectrofluorimetric

a

AZL

CONCENTRATION
(µg mL -1)

INTRA-DAY ASSAY
FOUND ± % R.S.Da

INTER-DAY ASSAY
FOUND ± %R.S.Da

12.000

12.619 ± 0.63

12.124 ± 1.68

20.000

20.124 ± 2.02

20.258 ± 1.01

30.000

29.813 ± 1.23

29.457 ± 1.19

4.000

4.028 ± 0.32

4.051 ± 0.64

8.000

7.905 ± 1.63

8.054 ± 1.66

12.000

11.923 ± 1.08

11.789 ± 1.58

0.015

0.015 ± 2.09

0.015 ± 2.92

0.030

0.030 ± 2.22

0.030 ± 2.77

0.050

0.050 ± 1.36

0.050 ± 2.88

Mean and % R.S.D. of three determinations.

v alidated for determination of AZL in its combination with
CLT either in their laboratory prepared mixtures or in their
combined pharmaceutical formulation. The proposed methods have many advantages regarding analysis time, sensitivity, and cost. Finally, the proposed methods can be used for
the quality control of the cited drugs in ordinary laboratories
without pre-separation.
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